Iovance shares moved higher after the company announced a $89.7 million stock sale. Investors shrugged off the potential overhang. New York, June 23, 2026, 17:04 (EDT)
Iovance Biotherapeutics (IOVA) jumped 9.4% to $4.44 late Tuesday, picking up about $159 million in market value. The move came as a new share-sale program had investors debating dilution risks versus the potential for quicker Amtagvi sales. Shares hit $4.52 during the session, with volume around 17.9 million shares.
Iovance set up an at-the-market offering, registering up to $89.65 million in stock for sale through Jefferies. That’s a smaller amount than what “shelf” usually implies. The at-the-market structure lets the company sell shares into the open market over time, not all at once. Iovance also said it has already sold around $260.35 million of stock under its prior prospectus and will stop using that old filing.
The upshot for investors: what’s the tradeoff between dilution and added cash. At the assumed $3.93 price in the filing, selling the full amount means about 22.8 million new shares, or 5.2% of Iovance’s 438.1 million share count as of March 31. Iovance said the raise would back the Amtagvi roll-out and its clinical work, like the IOV-LUN-202 lung cancer study and TILVANCE-301 in melanoma.
The move was notable since growth stocks sold off on Tuesday. The Nasdaq Composite dropped 2.2% and the S&P 500 slipped 1.4%. But biotech didn’t track the weakness: the SPDR S&P Biotech ETF gained 0.8% and the iShares Nasdaq Biotechnology ETF added 0.6%.
Iovance isn’t just a development story anymore. The stock calculus shifts after the company posted first-quarter product revenue of $71.43 million, up from $49.32 million in the same quarter last year. U.S. Amtagvi sales made up about $60 million. Proleukin brought in $11 million. Iovance is targeting $350 million to $370 million in product revenue in 2026.
Iovance’s interim CEO Frederick Vogt said in May the company was “accelerating the adoption and commercial expansion” of Amtagvi to meet record demand and pointed to manufacturing efficiencies and cost cuts aimed at helping margins. Tuesday’s market action shows investors are betting the equity raise will fuel the Amtagvi rollout, not just serve as a bailout. GlobeNewswire
Amtagvi is a TIL therapy that takes immune cells from the patient’s tumor, grows them outside the body, and gives them back as a one-time treatment. Iovance said earlier this month that Australia gave Amtagvi conditional approval for advanced melanoma in patients who’ve already been treated. That makes it the third marketing nod for the therapy. Vogt said Australia is important since it has the “highest rate of melanoma globally.” GlobeNewswire
Access is the key commercial detail for investors, not just approval. Iovance said demand and referrals are up at over 90 U.S. and Canadian authorized treatment centers and it’s looking for at least 110 of those to be active by year-end. The company also reported Amtagvi turnaround time at 32 days or less. Quick turnaround is critical for a personalized cell therapy, since delays can hit revenue.
The competitive field isn’t crowded, but it matters. Adaptimmune’s Tecelra, an autologous T-cell therapy for solid tumors, got FDA accelerated approval in synovial sarcoma in 2024. Adaptimmune then agreed to sell Tecelra and its cell-therapy assets to US WorldMeds. That puts focus on Iovance’s push to finance its launch and pipeline—investors are watching that as a sign for where solid-tumor cell therapy goes next.
Iovance’s balance sheet is still the main reason it keeps the ATM open. The company ended March with $319.4 million in cash, equivalents, short-term investments, and restricted cash. It burned through $72.1 million of cash on operations in the first quarter. A full $89.65 million draw, before costs, would cover around 1.2 quarters based on that level of spending.
Iovance flagged the risk from its ATM, saying these sales could trigger “immediate and substantial dilution.” The company said dumping a lot of shares on the market might hit the price. If Amtagvi uptake lags, payors pull back, manufacturing hits problems or clinical data comes in weak, the ATM could extend the runway but leave earnings looking the same.
Revenue is the next big test. Iovance expects second-quarter product revenue at $86 million to $88 million, with $79 million to $81 million from U.S. Amtagvi. Hitting those numbers would make Tuesday’s rally look less like pure speculation and more like the market adjusting for a commercial biotech facing manageable dilution.
